Clinicopathological features of patients with Wilms’s tumour
| Case | Stage | Age | Sex | Histopathology | Metastases | Histological features | |||
|---|---|---|---|---|---|---|---|---|---|
| % EP | % BL | % STR | M | ||||||
| Tumours exhibiting muscle are designated “heterotypic Wilms’s tumours”, whereas tumours with no evidence of muscle are designated “homotypic Wilms’s tumours”. | |||||||||
| *Tumours included for western blot analysis. | |||||||||
| BL, blastemal; EP, epithelial; FH, favourable histology; M, muscle; N/A, not available; STR, stromal; UF, unfavourable histology (anaplasia). | |||||||||
| Paired primary and metastatic tumour samples | |||||||||
| WiT 49p | II | 3 years | F | UF | – | 30 | 60 | 10 | Yes |
| WiT 49m | IV | 4 years | UF (diffuse) | Lung | 30 | 60 | 10 | Yes | |
| WiT 135 | III | 5 years | F | FH | – | 15 | 80 | 5 | No |
| WiT 135x | III | 5 years | FH | Lymph | 15 | 80 | 5 | No | |
| WiT 100 | II | 3 years | M | UF (diffuse) | – | 5 | 60–70 | 20–25 | Yes |
| WiT 108 | IV | 4 years | FH | Liver | 5 | 95 | 0 | No | |
| WiT 156* | II | 6 years | M | FH | – | 20 | 70 | 10 | No |
| WiT 157v | IV | 6 years | FH | Lymph | 20 | 70 | 10 | No | |
| WiT 168v | III | 8 years | F | FH | Lymph | 5 | 95 | 0 | No |
| WiT 167v | IV | 8 years | FH | Lung | 5 | 95 | 0 | No | |
| WiT 131v | II | N/A | M | UF (diffuse) | – | 10 | 60 | 30 | Yes |
| WiT 151v | III | N/A | UF (diffuse) | Pleural mass | 30 | 60 | 10 | Yes+adipose | |
| WiT 149v | III | 4 years | F | FH | Hilar lymph | 5 | 80 | 15 | No |
| WiT 149w | IV | 4 years | FH | Lung | 5 | 80 | 15 | No | |
| WiT 140 | II | 4 years | F | FH | – | 5 | 75 | 20 | No |
| WiT 140v | IV | 4 years | FH | Lung | 5 | 75 | 20 | No | |
| WiT 146* | I | 6 years | F | FH | – | 5 | 85 | 10 | No |
| WiT153 | II | 7 years | UF (focal) | Omentum | 5 | 85 | 10 | No | |
| Unpaired primary tumour samples | |||||||||
| WiT 180 | II | 5 years | F | UF (diffuse) | – | 30 | 40 | 30 | Yes+cartilage |
| WiT 173 | II | 5 years | F | FH | – | 10 | 85 | 5 | No |
| WiT 178 | II | 3 years | M | FH | – | 10 | 80 | 10 | Yes |
| WiT 176 | II | 5 years | F | FH | – | 20 | 70 | 10 | No |
| WiT 179 | II | 5 years | F | UF (diffuse) | – | 60 | 30 | 10 | No |
| WiT 175 | I | 1 year | M | FH | – | 60 | 0 | 40 | Yes |
| WiT 183 | II | 3 year | F | FH | – | 25 | 65 | 10 | No |
| WiT 158* | I | 2 year | F | FH | – | 65 | 30 | 5 | Yes |
| WiT 148 | II | 9 months | M | FH | – | 15 | 70 | 15 | No |
| WiT 141* | II | 6 years | M | FH | – | 60 | 10 | 30 | Yes |
| WiT 154* | I | 3 years | M | FH | – | 25 | 45 | 30 | No |
| Unpaired metastatic samples | |||||||||
| WiT 168 | IV | 5 years | M | FH | Adrenal | 2 | 95 | 3 | Yes |
| Hilar lymph | 95 | 2 | 3 | No | |||||
| Inter-aortocaval lymph | 95 | 2 | 3 | No | |||||
| WiT 144v | III | 1 years | F | FH | Peri-aortic lymph | 60 | 20 | 20 | Yes |
| WiT 183v | IV | 12 years | M | FH | Neck | 10 | 50 | 40 | No+cartilage |
| WiT 172 | III | 5 years | F | FH | Hilar lymph | 10 | 60 | 30 | No |
| WiT 123 | IV | 6 years | F | UF (focal) | Lung | 30 | 70 | 0 | No |
| WiT 157* | III | 8 years | M | FH | Pericaval lymph | 20 | 60 | 20 | Yes |
| WiT 181v | IV | 1 years | M | FH | Lung | 10 | 20 | 70 | No |
| WiT 190 | III | 3 years | M | FH | Mass below spleen | 30 | 60 | 5 | No |